NCT07169331View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Waldenström's Macroglobulinemia
Interventions
DRUG

Zanubrutinib

Administered orally

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY